Trials Sponsors Conditions Drugs Pricing

Conditions

Biomarkers Cervical Cancer Cervical Intraepithelial Neoplasia HIV/AIDS HPV

Keywords

Cervical CancerHIV/AIDSHPVBiomarkersScreening

Outcome Measures

Primary Outcomes (1)

Cervical Intraepithelial Neoplasia Grade II or more severe
Cervical Intraepithelial Neoplasia Grade II or more severe
At enrollment

Study Arms (1)

Cohort

HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, andBelgaum in India.

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The study population will be selected from HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, and Belgaum in India.

You may qualify if:

Female greater than or equal to 18 years of age at study entry. This ensures that all participants are at or above legal age in India for giving informed consent.

Sponsors & Collaborators

National Cancer Institute (NCI)
NIHlead

Study Sites (1)

National Institute of Epidemiology (NIE)

Chennai, India

Related Publications (3)

Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011 Sep;6(9):1083-98. doi: 10.2217/fmb.11.87.
PMID: 21958146BACKGROUND
Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, Tokugawa D, Bodelon C, Poitras N, Lorey T, Kinney W. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. J Natl Cancer Inst. 2015 Sep 15;107(12):djv257. doi: 10.1093/jnci/djv257. Print 2015 Dec.
PMID: 26376685BACKGROUND

MeSH Terms

Conditions

Uterine Cervical NeoplasmsAcquired Immunodeficiency SyndromeUterine Cervical Dysplasia

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

Nicolas Wentzensen, M.D.
National Cancer Institute (NCI)
PRINCIPAL INVESTIGATOR

Enrollment

1,000 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: CROSS SECTIONAL
Sponsor Type: NIH
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 20, 2014

First Posted

September 25, 2014

Study Start

November 28, 2012

Actual (reported)

Improving Cervical Cancer Screening Among HIV-Infected Women in India

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Cohort

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Cohort

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations